{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009989","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2025-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.116987+00:00","generated_at":"2026-05-17T21:43:19.210287+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Protalix BioTherapeutics resolves stockholder class action; pays $160k fees","bullets":["Plaintiff Kevin Mathew Thomas filed suit on March 10, 2025, challenging certain bylaws provisions under Delaware law.","On May 8, 2025, the Board amended the challenged bylaws, rendering plaintiff's claims moot.","Company agreed to pay $160,000 in fees and expenses to plaintiff's counsel; no admission of wrongdoing.","Court entered dismissal with prejudice as to plaintiff on July 23, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009989","json":"https://secwatch.observer/filing/0001558370-25-009989.json","markdown":"https://secwatch.observer/filing/0001558370-25-009989.md","text":"https://secwatch.observer/filing/0001558370-25-009989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025009989/0001558370-25-009989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837025009989/plx-20250801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:43:19.210287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}